Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
REDWOOD CITY, Calif., March 01, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at two upcoming investor healthcare conferences.
- Management participation in a fireside chat at the 38th Cowen & Company Healthcare Conference on Monday, March 12th at 2:50 p.m. ET taking place in Boston, MA.
- Management participation in a fireside chat is scheduled at Barclays Global Healthcare Conference on Wednesday, March 14th at 11:15 a.m. ET taking place in Miami, FL.
The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
